Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib-Reference-Cited by-同舟云学术

Predicting Drug-Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib

Published:2014-12-15 Issue:2 Volume:97 Page:177-185
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Shi JG¹,Fraczkiewicz G²,Williams WV¹,Yeleswaram S¹

Affiliation:

1. Incyte Corporation; Wilmington Delaware USA

2. Simulations Plus, Inc.; Lancaster California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference28 articles.

1. Drug interactions evaluation: an integrated part of risk assessment of therapeutics;Zhang;Toxicol. Appl. Pharmacol.,2010

2. US Food and Drug Administration Draft guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf 2012

3. European Medicines Agency Guideline on the investigation of drug interactions http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf 2012

4. Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug;Vieira;Clin. Pharmacol. Ther.,2014

5. vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet;Greenblatt;Clin. Pharmacol. Ther.,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19

2. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review;Clinical Pharmacokinetics;2023-03-31

3. Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells;Polymers;2023-02-15

4. PBPK modeling for early clinical study decision making;Overcoming Obstacles in Drug Discovery and Development;2023

5. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients;Pharmaceutics;2022-11-22